1. Home
  2. HTCR vs PCSA Comparison

HTCR vs PCSA Comparison

Compare HTCR & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

HOLD

Current Price

$3.30

Market Cap

6.5M

Sector

Technology

ML Signal

HOLD

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.87

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTCR
PCSA
Founded
2009
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
6.1M
IPO Year
2022
2012

Fundamental Metrics

Financial Performance
Metric
HTCR
PCSA
Price
$3.30
$2.87
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
218.6K
48.6K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
81.76%
N/A
EPS Growth
414.29
N/A
EPS
0.22
N/A
Revenue
$30,407,229.00
$5,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.52
N/A
P/E Ratio
$14.45
N/A
Revenue Growth
39.19
N/A
52 Week Low
$0.15
$0.11
52 Week High
$3.97
$8.88

Technical Indicators

Market Signals
Indicator
HTCR
PCSA
Relative Strength Index (RSI) 74.09 52.04
Support Level $0.42 $1.96
Resistance Level $3.97 $3.26
Average True Range (ATR) 0.26 0.31
MACD 0.28 0.02
Stochastic Oscillator 82.19 53.22

Price Performance

Historical Comparison
HTCR
PCSA

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: